Sugi Predict

Sugi Predict / Targets / CD59

CD59

CD59 glycoprotein · P13987 · CD59 on Sugi Atlas →

0 patent compounds predicted against CD59, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to CD59 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS PHASE4COMPLETED
A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC GENERIUM, Russian Federation) PHASE3COMPLETED
Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria PHASE3COMPLETED
Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria PHASE3COMPLETED
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation PHASE3COMPLETED
Daratumumab in Combination With ATRA PHASE1/PHASE2COMPLETED
An Open Label Study of the Effects of Eculizumab in CD59 Deficiency PHASE1/PHASE2UNKNOWN
Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis PHASE2COMPLETED
Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells PHASE1/PHASE2RECRUITING
A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies PHASE1/PHASE2RECRUITING
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances PHASE1/PHASE2RECRUITING
CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas PHASE1/PHASE2RECRUITING
CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL) PHASE1COMPLETED
Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL PHASE1UNKNOWN
CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia PHASE1UNKNOWN
CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas PHASE1COMPLETED
CD5CAR-NK Cells for Refractory Invasive Mold Disease PHASE1NOT_YET_RECRUITING
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen PHASE1RECRUITING
Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL EARLY_PHASE1RECRUITING
Endothelial Function in Obstructive Sleep Apnea EARLY_PHASE1COMPLETED
The Pharmacokinetics and Pharmacodynamics of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria nanCOMPLETED
The Molecular Biology of Paroxysmal Nocturnal Hemoglobinuria (PNH) nanCOMPLETED
Complement and Graft-versus-host Disease nanCOMPLETED
Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria® nanCOMPLETED
Transfer of GPI-Linked Proteins to Transfused Patients With Paroxysmal Nocturnal Hemoglobinuria nanCOMPLETED
CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors nanRECRUITING
Complement Activation in the Lysosomal Storage Disorders nanWITHDRAWN
A Real-world, Multi-center, Prospective, Observational Study for PNH in China nanCOMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN
Thymoglobulin: Presence and Affect in the Central Lymphatic Compartment nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CD59 binder may also engage these)

ProteinNameSimilarity
P47777 — 1.000 P47777 →
Q5R510 — 1.000 Q5R510 →
Q28216 — 1.000 Q28216 →
Q28785 — 0.997 Q28785 →
P35460 — 0.997 P35460 →
P51447 — 0.997 P51447 →
Q8SQ46 — 0.996 Q8SQ46 →
P46657 — 0.995 P46657 →
P27274 — 0.994 P27274 →
O55186 — 0.994 O55186 →
O62680 — 0.993 O62680 →
P58019 — 0.991 P58019 →
O77541 — 0.988 O77541 →
Q9WU67 — 0.987 Q9WU67 →
P35461 — 0.986 P35461 →
P05533 — 0.986 P05533 →
P0CW03 — 0.986 P0CW03 →
P83107 — 0.985 P83107 →
P57096 — 0.984 P57096 →
Q00996 — 0.984 Q00996 →
P0CW02 — 0.983 P0CW02 →
O95867 — 0.983 O95867 →
Q924B5 — 0.982 Q924B5 →
Q9Z1Q4 — 0.981 Q9Z1Q4 →
Q9GK77 — 0.981 Q9GK77 →
Q9D7Z7 — 0.981 Q9D7Z7 →
Q8NI32 — 0.981 Q8NI32 →
Q6UXB3 — 0.981 Q6UXB3 →
Q63317 — 0.981 Q63317 →
Q9DD23 — 0.980 Q9DD23 →